Click image to enlarge
Please note: MSD has transitioned this product to a status of “made-to-order” with a minimum order size of 25 plates. For an order of the 5-plate pack size, the minimum quantity is 5 packs (25 plates). The 1-plate and 20-plate pack sizes have been discontinued.
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Application(s)
|
|
Phosphoproteins
,
Intracellular Signaling
|
|
|
Analyte(s)
|
|
S6RP
|
|
|
Species
|
|
Human, Mouse, Rat
|
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
MESO SECTOR S 600MM
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120MM
,
MESO QuickPlex SQ 120
,
MESO SECTOR S 600
|
|
|
Plate Type
|
|
96-well
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Phosphatase Inhibitor I 0.5mL
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
Phosphatase Inhibitor II 0.5mL
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
Protease Inhibitor Solution 0.5mL
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
SULFO-TAG Anti-Total S6RP Antibody
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
Phospho(Ser240/244)/Total S6RP Plate
|
2-8 °C
|
5 each
(1 each)
|
|
|
|
|
2-8 °C
|
1 bottle
(50 mL)
|
|
|
|
|
2-8 °C
|
1 bottle
(200 mL)
|
|
|
|
|
RT
|
1 bottle
(50 mL)
|
|
|
|
|
RT
|
1 bottle
(15 g)
|
|
|
|
|
≤-10 °C
|
1 vial
(0.2 mL)
|
|
|
|
Product Inserts
|
|
|
|
Datasheets
|
|
|
|
Certificate of analysis
|
|
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
|
|
|
|
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
|
|
|
|
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.
|
|
|
|
Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
|
|
|
|
mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations.
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Meso Scale Japan 株式会社